Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March
2019
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Forxiga
approved in Japan for type-1 diabetes
27
March 2019 07:00 GMT
Forxiga approved in Japan for type-1
diabetes
The
Japanese Ministry of Health, Labour and Welfare (MHLW) has
approved Forxiga(dapagliflozin) as an oral
adjunct treatment to insulin for adults with type-1 diabetes
(T1D).
Elisabeth Björk, Senior Vice President, Head of late
Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals,
said: "This approval of Forxiga in Japan means that people with type-1
diabetes whose glucose levels are not adequately controlled with
insulin alone now have a new oral treatment option available to
them. Forxiga will help address a significant unmet need
in this patient population, and this approval in type-1 diabetes
builds on the well-established clinical profile
of Forxiga."
The
approval is based on data from the Phase III
DEPICT clinical programme and a dedicated trial in Japanese
patients (D1695C00001). Results showed that Forxiga, when given as an oral
treatment in addition to adjustable insulin in patients with
inadequately-controlled T1D, demonstrated significant and
clinically-meaningful reductions from baseline in average blood
glucose levels HbA1c (primary endpoint), weight and total daily
insulin dose (secondary endpoints) at 24 weeks1,2,3, at both 5mg and
10mg doses.
The
safety profile of Forxiga in these T1D trials was
consistent with its well-established profile in type-2 diabetes
(T2D), with the exception of a higher number of diabetic
ketoacidosis (DKA) events in Forxiga-treated patients versus
placebo. DKA is a known complication for adults with T1D that
affects those with T1D more frequently than with
T2D. Forxiga is
already indicated as a monotherapy and as part of combination
therapy in adults with T2D to improve glycaemic control as an
adjunct to diet and exercise.
Forxiga was approved by the European Commission on 20
March as an adjunct treatment to insulin in adults with T1D, and
the medicine is under regulatory review in the US for the same
indication, with a decision expected in the second half of
2019.
About type-1 diabetes
T1D is a chronic disease in which the pancreas produces little or
no insulin. Approximately five percent of people living with
diabetes have type-1. The condition is caused by an autoimmune
reaction that destroys the beta cells in the pancreas which make
insulin.4 Different
factors, including genetics and some viruses, may contribute to
type-1 diabetes.5
About the DEPICT clinical programme
The DEPICT (Dapagliflozin Evaluation
in Patients
with Inadequately Controlled Type
1 Diabetes) clinical trial programme consists of two trials:
DEPICT-1 and DEPICT-2 which are 24-week, randomised,
double-blinded, parallel-controlled trials designed to assess the
effects of Forxiga 5mg or 10mg on glycaemic control in patients
with T1D inadequately controlled by insulin. All patients were
evaluated at week 24 and after a 28-week extension (52 weeks in
total).
About Forxiga
Forxiga (dapagliflozin) is a first-in-class, oral once-daily selective
inhibitor of human sodium-glucose co-transporter 2 (SGLT2)
indicated as both monotherapy and as part of combination therapy to
improve glycaemic control, with the additional benefits of weight
loss and blood pressure reduction, as an adjunct to diet and
exercise in adults with T2D. Forxiga has a robust clinical trial programme of
more than 35 completed and ongoing Phase IIb/III trials in over
35,000 patients, as well as more than 1.8 million patient-years'
experience. Outside T2D, Forxiga is also approved in T1D in the
EU.
About AstraZeneca in Cardiovascular, Renal & Metabolism
(CVRM)
Cardiovascular, renal and metabolism together form one of
AstraZeneca's main therapy areas and a key growth driver for the
Company. By following the science to understand more clearly the
underlying links between the heart, kidneys and pancreas,
AstraZeneca is investing in a portfolio of medicines to protect
organs and improve outcomes by slowing disease progression,
reducing risks and tackling co-morbidities. Our ambition is to
modify or halt the natural course of CVRM diseases and potentially
regenerate organs and restore function, by continuing to deliver
transformative science that improves treatment practices and
cardiovascular health for millions of patients
worldwide.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please
visit astrazeneca.com and
follow us on Twitter@AstraZeneca.
|
Media
Relations
|
|
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
|
Jennifer
Hursit
|
UK/Global
|
+44
203 749 5762
|
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharma
- Cardiovascular; Metabolism
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharma
- Respiratory; Renal
|
+44 203
749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Retail
Investors; Corporate Access
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
References
1.
Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of
dapagliflozin in patients with inadequately controlled type 1
diabetes (DEPICT-1): 24-week results from a randomised controlled
trial. Lancet Diabetes and Endocrinol. 2017:5;846-17
2. Mathieu
C, Dandona, P, Gillard, P, et al. Efficacy and Safety of
Dapagliflozin in Patients With Inadequately Controlled Type 1
Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized
Controlled Trial. Diabetes Care 2018;41:1938-1946
3.
Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of
dapagliflozin in patients with inadequately controlled type 1
diabetes: The Depict-1 52 week study. Diabetes Care 2018 Dec;
41(12): 2552-2559
4.
"Diabetes Home." Centers for Disease Control and Prevention,
Centers for Disease Control and Prevention, 15 Aug. 2018,
www.cdc.gov/diabetes/basics/type1.html.
5.
"Type 1 Diabetes." Mayo Clinic, Mayo Foundation for Medical
Education and Research, 7 Aug. 2017,
www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
27 March
2019
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|